Birmingham’s National NMR Hub Advances UK Biomolecular and Solid-State Research with World-Leading NMR Technology
Birmingham, UK – December 1st, 2025 – Bruker Corporation (Nasdaq: BRKR), a global leader in scientific instrumentation, today announced the successful installation of its 1.2 GHz Nuclear Magnetic Resonance (NMR) spectrometer at the University of Birmingham’s Henry Wellcome Building for Biomolecular NMR (HWB-NMR). With funding from the Engineering and Physical Sciences Research Council (EPSRC) and the University of Birmingham, this milestone strengthens the UK’s research infrastructure for biomolecular and solid-state NMR, while introducing an additional ultra-high-field 1.2 GHz NMR spectrometer to advance scientific discovery.
The HWB-NMR facility serves as a cross-college and national resource, supporting the Colleges of Life and Environmental Sciences (LES), Medicine and Health (CMH), and Engineering and Physical Sciences (EPS), as well as the broader UK biomolecular solution and solid-state NMR community. The 1.2 GHz spectrometer enables the study of complex molecular machineries and dynamic systems, including disordered biomolecules and RNA-protein complexes. These capabilities open new avenues for research into gene expression, DNA repair, signal transduction, and the structural and dynamic effects of RNA modifications. The facility’s integrative approach, combining NMR with electron microscopy, X-ray crystallography, mass spectrometry, light microscopy, and computational methods, provides a comprehensive view of molecular machinery in time and space.
“The acceptance of the 1.2 GHz NMR spectrometer marks a pivotal moment for our research community,” said Professor Teresa Carlomagno, Head of HWB-NMR. “NMR spectroscopy is uniquely powerful in revealing the dynamics and disorder that underlie molecular mechanisms in health and disease - capabilities that are often inaccessible to other structural biology techniques. By integrating NMR with complementary methods, we can achieve a deeper understanding of molecular assemblies and their internal motion, enabling us to address questions about structure, function, and dynamics that are critical for advancing biomolecular science.”
The 1.2 GHz NMR spectrometer will accelerate breakthroughs in health and disease research at the molecular level, supporting targeted therapies, sustainable biomaterials, and innovations from drug design to synthetic biomolecules. Building on these capabilities, the University of Birmingham will advance Molecular Biodiscovery within an integrative structural biology framework, driving cross-disciplinary collaboration to keep HWB-NMR at the forefront of scientific discovery.
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
Media Contact
Markus Ziegler
Sr. Director and Head of Group Marketing
Bruker BioSpin
T: +49 172 3733531
E: pr@bruker.com
